(Q74362706)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

Immunotherapy for bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

A M Kamat

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

D L Lamm

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 February 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

published in

Current urology reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

62-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084297%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11934-001-0027-7

10 November 2019

exact match

0 references

cites work

Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy

1 reference

12 December 2020

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

1 reference

12 December 2020

Superficial bladder cancer: progression and recurrence

1 reference

12 December 2020

Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer

1 reference

12 December 2020

Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG

1 reference

12 December 2020

Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity

1 reference

12 December 2020

Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy

1 reference

12 December 2020

Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer

1 reference

12 December 2020

Bacillus Calmette-Guerin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction.

1 reference

12 December 2020

Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study

1 reference

12 December 2020

Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III

1 reference

12 December 2020

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer

1 reference

12 December 2020

[BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder]

1 reference

12 December 2020

Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system

1 reference

12 December 2020

Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors

1 reference

12 December 2020

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

1 reference

12 December 2020

Internalization of bacille Calmette-Guerin by bladder tumor cells.

1 reference

12 December 2020

Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.

1 reference

12 December 2020

Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours

1 reference

12 December 2020

Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin

1 reference

12 December 2020

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

12 December 2020

Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma

1 reference

12 December 2020

Allium sativum (garlic) treatment for murine transitional cell carcinoma

1 reference

12 December 2020

Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.

1 reference

12 December 2020

Interleukin-12. Opportunities for the treatment of bladder cancer.

1 reference

12 December 2020

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

1 reference

12 December 2020

Bacillus Calmette-Guérin treatment and vesicorenal reflux

1 reference

12 December 2020

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

1 reference

12 December 2020

The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer

1 reference

12 December 2020

Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study

1 reference

12 December 2020

Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results

1 reference

12 December 2020

Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group

1 reference

12 December 2020

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

12 December 2020

Megadose vitamins in bladder cancer: a double-blind clinical trial

1 reference

12 December 2020

Transurethral resection and intravesical therapy of superficial bladder tumors

1 reference

12 December 2020

Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies

1 reference

12 December 2020

Interferons and bladder cancer

1 reference

12 December 2020

Clinical application of a whole blood assay for human natural killer (NK) cell activity

1 reference

12 December 2020

Antitumor activity of interleukin-12 against murine bladder cancer

1 reference

12 December 2020

Long-term results of intravesical therapy for superficial bladder cancer

1 reference

12 December 2020

[Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses]

1 reference

12 December 2020

Antiproliferative Activities of Interferons Against Human Bladder Carcinoma Cell Lines in Vitro

1 reference

12 December 2020

Bacille Calmette-Guérin in superficial transitional cell carcinoma

1 reference

12 December 2020

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

1 reference

12 December 2020

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

1 reference

12 December 2020

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

12 December 2020

Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients

1 reference

12 December 2020

In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate

1 reference

12 December 2020

Bacillus Calmette-Guerin immunotherapy for bladder cancer

1 reference

12 December 2020

Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha

1 reference

12 December 2020

A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?

1 reference

12 December 2020

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

1 reference

12 December 2020

BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study

1 reference

12 December 2020

Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

12 December 2020

Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule

1 reference

12 December 2020

Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder Tumors

1 reference

12 December 2020

Chemoprevention of urological cancer

1 reference

12 December 2020

Keyhole limpet hemocyanin immunotherapy of murine bladder cancer

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials

1 reference

12 December 2020

Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor

1 reference

12 December 2020

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

1 reference

12 December 2020

Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor

1 reference

12 December 2020

Cytologic and histologic features of superficial bladder cancer

1 reference

12 December 2020

Management of local bacillus Calmette-Guerin failures in superficial bladder cancer

1 reference

12 December 2020